News & Analysis as of

Inflation Reduction Act (IRA)

ArentFox Schiff

Top Legal Challenges for the Health Care Industry in 2026

ArentFox Schiff on

With 2026 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year....more

DLA Piper

Three New Drug Pricing Models For Manufacturer Rebates: Key Implications

DLA Piper on

The Center for Medicare and Medicaid Innovation (CMMI) recently released information about three new models aimed at testing alternative calculations for manufacturer rebates, to ensure net drug prices are closer to those in...more

McDermott Will & Schulte

Nuclear power projects gain momentum as federal tax incentives, data center demand transform financing landscape

With electricity demand rising across the United States, nuclear power is receiving renewed attention from energy developers, investors, and financiers – both for existing facilities and new projects....more

Bricker Graydon LLP

Foreign Entity of Concern Rules: A Quick Overview for Clean Energy Stakeholders

Bricker Graydon LLP on

The clean energy industry is at a crossroads. The One Big Beautiful Bill Act (OBBBA) introduced sweeping restrictions on Foreign Entities of Concern (FEOCs), fundamentally changing how developers, manufacturers, and investors...more

Polsinelli

CMS Proposes GLOBE and GUARD Drug Pricing Models to Reduce Medicare Costs

Polsinelli on

Key Takeaways: CMS has proposed two mandatory Medicare drug pricing models: the GLOBE Model (for Part B drugs) and the GUARD Model (for Part D drugs)....more

Knobbe Martens

Life Science Update | December 2025

Knobbe Martens on

A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11 plan to settle thousands of opioid-related lawsuits. The plan requires (1) a $6.5 billion contribution from the Sackler family...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - December 2025 #3

Latham & Watkins LLP on

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more

Husch Blackwell LLP

Proposed Bill Would Revive Slashed OBBBA Energy Tax Credit Cuts

Husch Blackwell LLP on

On October 29, 2025, Democratic members of the House Ways and Means Committee introduced H.R. 5862, the American Energy Independence and Affordability Act (the Bill). The legislation, introduced by Rep. Mike Thompson...more

Mintz - Health Care Viewpoints

CMS Targets Rising Drug Costs with New Guard and Globe Pilot Programs

On Friday, December 19, the Centers for Medicare & Medicaid Services (CMS) announced two new pilot programs aimed at reducing Medicare spending on prescription drugs and reducing beneficiaries’ out-of-pocket costs. The...more

McDermott Will & Schulte

ASP reporting gets a major update in the CY 2026 PFS

McDermott Will & Schulte on

Drug manufacturers, group purchasing organizations, and other companies in the drug distribution chain will be impacted by the changes to average sales price (ASP) and bona fide service fees (BFSFs) adopted by the Centers for...more

Allen Matkins

California Environmental Law & Policy Update 12.19.25

Allen Matkins on

The U.S. Court of Appeals for the District of Columbia Circuit on Wednesday ruled that the nonprofit recipients of $14 billion in climate grants frozen by the U.S. Environmental Protection Agency can have their case reheard....more

Cadwalader, Wickersham & Taft LLP

Final Buyback Regulations Give Corporate Taxpayers Cause for Thanksgiving

On the day before Thanksgiving, the Treasury and IRS issued final regulations for the Section 4501 excise tax on stock repurchases. Enacted as part of the Inflation Reduction Act in 2022, Section 4501 imposes a 1% excise tax...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - December 2025 #2

Latham & Watkins LLP on

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more

Foley Hoag LLP - Energy & Climate Counsel

30 Years of New England Electricity Restructuring Roundtable

On December 5, 2025, Foley Hoag hosted the 30th Anniversary of the New England Electricity Restructuring Roundtable (“Roundtable”), convening leading regulators, executives, and policy experts in the region’s electric power...more

Epstein Becker & Green

The Next Chapter of Medicare Advantage and Part D: Key Takeaways from the 2027 Proposed Rule

Epstein Becker & Green on

On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS or the “Agency”) released the 2027 Medicare Advantage and Part D Proposed Rule (the “Proposed Rule”)....more

Lathrop GPM

U.S. Oil & Gas Outlook 2026: How Energy Companies Can Navigate a Plateau Year

Lathrop GPM on

2025 was expected to be a new golden age for traditional energy sources: the era of “drill, baby, drill,” under an administration intent on removing hurdles for producers. ...more

Brownstein Hyatt Farber Schreck

November 2025 Tax Regulatory Update

In September, the Treasury Department and Internal Revenue Service (IRS) issued the 2025-2026 Priority Guidance Plan. The plan outlines priority guidance projects to be addressed from July 1, 2025, through June 30, 2026. The...more

McDermott+

CMS releases 2027 policy and technical changes to Medicare Advantage and Part D proposed rule

McDermott+ on

On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that puts forth policy and technical changes to the Medicare Advantage (MA) and Part D programs for 2027 and beyond....more

Knobbe Martens

Patent Exclusivity and Price Controls: Teva v. Kennedy

Knobbe Martens on

On November 20, 2025, the DC District court issued its opinion [1] in a lawsuit where Teva Pharmaceuticals USA, Inc. challenged the validity of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act of...more

Sheppard Mullin Richter & Hampton LLP

Happy Holidays? CMS Contract Year 2027 Medicare Advantage and Part D Proposed Rule Has Winners and Losers

On November 25, 2025, CMS released the Contract Year (“CY”) 2027 Medicare Advantage (“MA”) and Part D proposed rule (the “Proposed Rule”). The Proposed Rule would make significant changes to the MA and Part D programs,...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - December 2025

Latham & Watkins LLP on

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more

Mintz - Health Care Viewpoints

CMS Releases the Proposed 2027 Medicare Advantage and Part D Rules

Last week, the Centers for Medicare & Medicaid Services (CMS) released its proposed Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare...more

Hogan Lovells

Final Regulations on the Section 4501 Excise Tax on the Repurchase of Corporate Stock

Hogan Lovells on

On November 24, 2025, the IRS published final regulations (the “Final Regulations”) providing comprehensive guidance on the application of the excise tax on repurchases of corporate stock under Section 4501, as enacted by...more

Alston & Bird

Health Care Week in Review | CMS releases CY 2027 Medicare Advantage and Part D Proposed Rule; Trump Administration Announces...

Alston & Bird on

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies,...more

DLA Piper

Keeping watch on Medicare: Drug plans, premiums, and availability under the Inflation Reduction Act

DLA Piper on

In 2026, there are fewer prescription drug plans in Medicare Part D and higher premiums, even when offset by a multi-billion-dollar government premium subsidy; this degradation of the Part D market is likely attributable to...more

1,849 Results
 / 
View per page
Page: of 74

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide